Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBALS open-label extension of high-dose ambroxol for amyotrophic lateral sclerosis
ACTRN12624001204538Phase 2Active, not recruiting
- Sponsor
- Florey Institute of Neuroscience and Mental Health
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambroxol in amyotrophic lateral sclerosis (ALS), sponsored by Florey Institute of Neuroscience and Mental Health. Primary endpoint: Time to composite event. Started Sep 2024; status: active, not recruiting.
02
Drugs
ambroxol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12624001204538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001204538.